“Is prostate cancer screening right for you?”

The following infographic was also issued today by the U.S. Preventive Services Task Force (USPSTF) and offers guidance as to the appropriateness of prostate cancer screening for an average, 55- to 69-year-old American male with no specific, known risk factors for prostate cancer: … READ MORE …

When is whole pelvic radiation needed for salvage post-prostatectomy?

Patients who elect to have post-prostatectomy radiation therapy for recurrent prostate cancer face a couple of important decisions: … READ MORE …

Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Can phi density accurately predict risk for clinically significant prostate cancer?

A new article in BJU International has suggested the possibility that Prostate Health Index density (i.e., a patient’s phi score divided by his prostate volume) may be able to predict the probability of a finding of clinically significant prostate cancer on biopsy. … READ MORE …

Another step toward a rational, risk-stratified PSA testing methodology

A newly published article in the Journal of Clinical Oncology has suggested that PSA testing between 40 and 59 years of age may be able to predict for risk of clinically significant prostate cancer later in life. … READ MORE …

New form of vaccine therapy — for low-risk prostate cancer

According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …

Statin therapy lowers mortality rates among Danish prostate cancer patients

According to a media release and a presentation given at the European Association of Urology (EAU) in Europe this week, statin therapy has a small but significant impact on overall and prostate cancer-specific mortality rates. … READ MORE …